NASDAQ:TELO Telomir Pharmaceuticals Q2 2026 Earnings Results & Report $1.12 -0.03 (-2.61%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.13 +0.01 (+0.89%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Telomir Pharmaceuticals missed analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.79 versus the -$0.07 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeBefore Market Opens Telomir Pharmaceuticals EPS ResultsActual EPS-$0.79Consensus EPS -$0.07Beat/MissMissed by -$0.72One Year Ago EPSN/AEPS Beat Rate4 of last 7 quartersTelomir Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTelomir Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Telomir Pharmaceuticals Q2 2026 Earnings FAQ Did Telomir Pharmaceuticals beat earnings estimates for Q2 2026? Telomir Pharmaceuticals (NASDAQ:TELO) reported earnings of -$0.79 per share for Q2 2026, missing the consensus estimate of -$0.07. The report was announced on Thursday, August 13, 2026. When is Telomir Pharmaceuticals' next earnings date? Telomir Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Telomir Pharmaceuticals on the company's earnings history page. Telomir Pharmaceuticals Earnings HeadlinesTelomir Pharmaceuticals, Inc. announced that it has received $5.618228 million in fundingOctober 6, 2026 | marketscreener.comMTelomir (NASDAQ: TELO) secures $5.6 million PIPE as DeJoria adds capitalOctober 6, 2026 | americanbankingnews.comThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.October 10 at 1:00 AM | Base Camp Trading (Ad)Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the CompanyOctober 6, 2026 | globenewswire.comResearch shows Telomir-Zn might slow bone cancer in dogsSeptember 24, 2026 | msn.comMaxim Initiates Telomir Pharmaceuticals at Buy With $4 Price TargetSeptember 18, 2026 | marketscreener.comMSee More Telomir Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email. Email Address About Telomir PharmaceuticalsTelomir Pharmaceuticals (NASDAQ:TELO) is a clinical-stage biotechnology company focused on developing treatments for age-related diseases and conditions associated with cellular aging. The company’s research centers on telomeres, protective structures at the ends of chromosomes that generally shorten as cells divide and age. Telomir’s lead investigational product is Telomir-1, a proprietary small-molecule compound designed to promote telomere lengthening and support cellular function. The company is evaluating its potential application in diseases associated with aging, including osteoarthritis and other conditions involving tissue degeneration. Telomir-1 remains an investigational therapy and is not an approved drug. Telomir Pharmaceuticals is pursuing preclinical and clinical development activities intended to establish the safety and effectiveness of its technology. As a development-stage biotechnology company, its primary activities include drug discovery, research collaborations, and advancing Telomir-1 toward potential regulatory approval rather than marketing commercial products.View Telomir Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part Begins Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
